Get the Stockscreener App
24.00
1.68%
-0.345
Olema Pharmaceuticals Inc stock is traded at $24.00, with a volume of 67,775.
It is down -1.68% in the last 24 hours and down -4.32% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$24.34
Open:
$23.95
24h Volume:
67,775
Relative Volume:
0.04
Market Cap:
$1.92B
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-11.16
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-1.88%
1M Performance:
-4.32%
6M Performance:
+187.98%
1Y Performance:
+461.76%
1-Day Range:
$23.52
$24.15
1-Week Range:
$22.88
$25.17
52-Week Range:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
23.93 | 1.95B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.48 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
734.61 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.00 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-26 | Initiated | Stifel | Buy |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Aug Intraday: Is Olema Pharmaceuticals Inc backed by strong institutional buyingPortfolio Value Report & Smart Money Movement Alerts - baoquankhu1.vn
Olma Health (NASDAQ: OLMA) director reports several stock sales in Jan–Feb 2026 - Stock Titan
Insider sells 15,000 OLMA shares; 25,000-share option sale planned (OLMA) - Stock Titan
OLMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Olema Pharmaceuticals Grants Stock Options to New Employees Under 2022 Inducement Plan - Quiver Quantitative
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
[144] Olema Pharmaceuticals, Inc. SEC Filing - Stock Titan
How Leadership Turnover and Palazestrant Optimism At Olema Pharmaceuticals (OLMA) Has Changed Its Investment Story - Sahm
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Olema Pharmaceuticals CEO to join TDCowen Health Care Conference fireside chat in Boston - Traders Union
Olema Pharmaceuticals CEO Touts Palazestrant Edge as Oral SERDs Shake Out at Conference - MarketBeat
How Leadership Turnover During Key Trial Milestones Will Impact Olema Pharmaceuticals (OLMA) Investors - Yahoo Finance
OLMA Should I Buy - Intellectia AI
Citi, Stifel Bullish on Olema (OLMA) Despite COO Departure - Yahoo Finance
Olema earnings on deck: Biotech faces widening loss ahead of key data - Investing.com South Africa
Olema Pharmaceuticals, Inc. (OLMA): Investor Outlook on a Promising Biotech with 91% Potential Upside - DirectorsTalk Interviews
20,000-share Form 144 filed for Olami Medical (NASDAQ: OLMA) - Stock Titan
Olema Pharmaceuticals CEO Spotlights Phase 3 Palazestrant Trials, KAT6 Program at Citi Summit - MarketBeat
Shane Kovacs sells 110,000 OLMA shares across Jan–Feb 2026 (NASDAQ: OLMA) - Stock Titan
OLMA (NASDAQ: OLMA) Form 144 shows proposed 20,000-share sale; prior insider sales listed - Stock Titan
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
OLMA Technical Analysis & ETF Price Forecast - Intellectia AI
Aug Drivers: Can JetBlue Airways Corporation reach resistance levels soonQuarterly Profit Report & Risk Managed Investment Signals - baoquankhu1.vn
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Is It Too Late To Consider Olema Pharmaceuticals (OLMA) After A 348% One‑Year Surge? - Yahoo Finance
Olema Pharmaceuticals (OLMA) sees 9.99% stake from Bain Capital - Stock Titan
Olema Nears Palazestrant Readout As Commercial Shift Raises Execution Risks - Yahoo Finance
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating - Yahoo Finance
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity? - Intellectia AI
Olema Pharmaceuticals CEO Teases Fall OPERA-01 Readout, Q2 KAT6 Data and CFO/COO Exit - MarketBeat
Published on: 2026-02-14 18:42:21 - mfd.ru
Is Olema (OLMA) Balancing Leadership Change and New Wall Street Attention to Refine Its Strategy? - Sahm
This Olema Pharmaceuticals analyst begins coverage on a bullish note; here are top 4 initiations for Wednesday - MSN
This Olema Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) with B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Stifel Nicolaus Initiates Coverage on Olema Pharmaceuticals With Buy Rating - marketscreener.com
Candriam S.C.A. Increases Stock Position in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Will Olema Pharmaceuticals Inc. stock benefit from automationJuly 2025 Closing Moves & Weekly High Return Stock Opportunities - mfd.ru
Stifel initiates Olema Pharmaceuticals stock with Buy rating, $48 target By Investing.com - Investing.com Canada
Olema Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Olema Oncology to Participate in Upcoming Investor Conferences - Sahm
Olema Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Olema Pharmaceuticals seeks NDA lead for biotech program - Traders Union
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Weekly Recap: Does Olema Pharmaceuticals Inc have pricing power2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Institutional Investors Control 63% of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) and Were Rewarded Last Week After Stock Increased 7.2% - 富途牛牛
Cancer index surges 72% as Terns, Olema lead gains - BioWorld MedTech
Investment Review: Is Olema Pharmaceuticals Inc stock trending bullishQuarterly Trade Summary & Consistent Return Strategy Ideas - baoquankhu1.vn
Pfizer-Olema Collaboration Targets Metastatic Breast Cancer - MSN
Olema Pharmaceuticals to Present at Upcoming Investor Conferences in February 2026 - Quiver Quantitative
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):